Naproxen-lysozyme conjugate

The different aspects of drug targeting using LMWPs that have been studied to date are discussed below. As an example, we use the data of two conjugates, naproxen-lysozyme and captopril-lysozyme. 

A spacer was used to link captopril via a disulfide bond to the LMWP lysozyme. Conjugation of captopril to lysoz5me resulted in a 6-fold increase in captopril accumulation in the rat kidney (Eigure 5.9b) [77]. This modest enrichment, as compared to that achieved with naproxen-lysozyme, was due to fact that, in contrast to naproxen, free captopril is cleared very efficiently by the kidney itself. Thus, delivery via lysozyme reabsorption only leads to a limited improvement of renal accumulation of captopril. 

Figure 5.9. The concentration-time course of (a) naproxen and (b) captopril in the kidney after intravenous injection of the parent drug or the drug-lysozyme (LZM) conjugate. Values are given as means + SEM.

---